Subscribe
jhve-1
JHVEPhoto / Shutterstock.com
26 August 2020AmericasRory O'Neill

Intercept sues Apotex over Ocaliva generic

Intercept Pharmaceuticals is suing Canadian generics manufacturer  Apotex over a proposed version of autoimmune drug  Ocaliva (obeticholic acid).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Takeda, Bayer settle $173m Adynovate suit
20 May 2021   Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
Americas
Orexo sues Sun Pharma over opioid dependence generic
16 September 2020   Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.
Big Pharma
Bayer, Apotex settle suit over cancer drug patent
13 August 2020   Bayer has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Takeda, Bayer settle $173m Adynovate suit
20 May 2021   Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
Americas
Orexo sues Sun Pharma over opioid dependence generic
16 September 2020   Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.
Big Pharma
Bayer, Apotex settle suit over cancer drug patent
13 August 2020   Bayer has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents.

More on this story

Americas
Takeda, Bayer settle $173m Adynovate suit
20 May 2021   Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
Americas
Orexo sues Sun Pharma over opioid dependence generic
16 September 2020   Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.
Big Pharma
Bayer, Apotex settle suit over cancer drug patent
13 August 2020   Bayer has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB